Biogen price target raised to $213 from $205 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Biogen (BIIB) to $213 from $205 and keeps an Outperform rating on the shares. After a major portfolio refocusing in recent years, Biogen’s pipeline is approaching a more catalyst-rich period entering 2026 and beyond, led by maturing I&I – Immunology and Inflammation – and neuro candidates, the analyst tells investors in a research note. With these more meaningful but under-the-radar pipeline drivers approaching, the firm sees considerable appreciation potential with limited downside risk, RBC added.